Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|September 8, 2015
Algorics Analytics Solution acuity Selected by US CRO Lexitas to Drive Optimized Clinical Operations Services
Author(s)Company Press Release
Advertisement
Houston, TX, USA, For Release: 8th September 2015. Algorics, a provider of clinical analytics solutions and software for the global life sciences industry, today announced that acuity, its analytics solution for risk based monitoring, has been adopted by Lexitas Pharma Services, Inc. The US Ophthalmology-focused CRO will leverage the acuity solution to bring together internal and external data sources in order to provide analytics dashboards and alerts to give the leadership team a real-time picture of key operational parameters and KRI (key risk indicators) and allow operational teams to more easily manage trial performance.
“As Lexitas grows we continue to look for innovative ways to improve efficiency without compromising the high quality and tailored services our clients count on. Implementing acuity will provide us with a timely and comprehensive view of how our portfolio of trials is performing, as well as enable us to manage individual trials in the most effective way,” said Chad Ice, President, Lexitas.
Nick Hargaden, President, Algorics said, “We are delighted that Lexitas has chosen acuity to provide centralized insights into the clinical trials they manage, thus driving operational effectiveness and resource savings.”
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5